SELLAS Life Sciences Group Inc
SLS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.45B
Close$
$0.65
94.7% downside
Current Fair Value
94.7% downsideOvervalued by 94.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.45 Billion |
|---|---|
| Enterprise Value | $2.35 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.25 |
| Beta | 2.43 |
| Outstanding Shares | 172,481,541 |
Return
| Return on Equity | -27.42% |
|---|---|
| Return on Assets | -25.80% |
| Return on Invested Capital | -28.68% |
Valuation & Multiples
| P/E Ratio | -57.77 |
|---|---|
| PEG | -129.47 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -75.97 |
| Enterprise Value to Net Income | -80 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 16.77% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.06%▼ 30.23% |
|---|---|
| Total Invested | $26.84M▼ 88.25% |
| Investors Holding | 21▼ 155.00% |
ESG Score
No data
About SELLAS Life Sciences Group Inc
7 employeesSELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Ketteri...